Abliva AB (publ)
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NEVPF research report →
Price Chart
About the company
Abliva AB (publ) is a pharmaceutical firm focused on developing novel treatments for primary mitochondrial disorders. Its product pipeline features KL1333, currently in Phase 2/3 clinical trials for the long-term management of these conditions. Another compound, NV354, is undergoing preparations for clinical studies, specifically targeting primary mitochondrial diseases linked to Complex I deficiency.
- CEO
- Ellen K. Donnelly
- IPO
- 2014
- Employees
- 6
- HQ
- Lund, SE
Get TickerSpark's AI analysis on NEVPF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $45.13M
- P/E
- -4.91
- Fwd P/E
- 3.11
- PEG
- -0.20
- P/S
- 5223.90
- P/B
- 7.60
- EV/EBITDA
- -7.30
- Div Yield
- 0.00%
- Gross Margin
- -50132.85%
- Op Margin
- -70472.99%
- Net Margin
- -69714.60%
- ROE
- -144.27%
- ROIC
- -156.50%
Latest fiscal year · YoY change
- Revenue
- $137.00K+0.0%
- Gross Profit
- $-68,682,000+0.0%
- Op Income
- $-96,548,000
- Net Income
- $-95,509,000+0.0%
- EPS
- $-0.09+0.0%
- OCF Growth
- -1218.1%
- FCF Growth
- -1044.2%
- 52W High
- $0.04
- 52W Low
- $0.01
- 50D MA
- $0.03
- 200D MA
- $0.02
- Beta
- 0.75
- RSI (14)
- 42
- Avg Volume
- 1.65K
No earnings-call transcripts are available for NEVPF yet.
- Free Float
- 7.3%
- Shares Outstanding
- 1.61B
- Float Shares
- 117.70M
Our NEVPF coverage
Recent articles, reports, and earnings notes.
No research on NEVPF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NEVPF report →Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.